CI 8-K
Cigna Group (CI)
8-K
2026-02-05
For: 2026-02-05
View Original
Added on
April 03, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 5, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
(860 ) 226-6000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On February 5, 2026, The Cigna Group issued a press release announcing results for the three months and year ended December 31, 2025. The press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as expressly set forth by specific reference in such a
filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
Press release dated February 5, 2026.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
THE CIGNA GROUP
|
||
|
Date: February 5, 2026
|
By:
|
/s/ Ann M. Dennison
|
|
Ann M. Dennison
|
||
|
Executive Vice President and Chief Financial Officer
|
||
Exhibit 99.1
|
Press Release
|
 |
INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
860-787-7968
MEDIA CONTACT:
Justine Sessions
860-810-6523
The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results,
Establishes 2026 Outlook and Increases Dividend
| • |
Total revenues for 2025 increased 11% to $274.9 billion
|
| • |
Shareholders’ net income for 2025 was $6.0 billion, or $22.18 per share
|
| • |
Adjusted income from operations1 for 2025 was $8.0 billion, or $29.84
per share
|
| • |
2026 adjusted income from operations1 is projected to be at least $7.950 billion, or
at least $30.25 per share2
|
| • |
Board of Directors declared an increase in the quarterly dividend to $1.56 per share
|
BLOOMFIELD, CT, February 5, 2026 – Global health company The Cigna Group (NYSE: CI) today reported
2025 results, underscoring operational discipline and the strength of its complimentary portfolio of global health businesses.
“In 2025, we expanded access and support, lowered costs, and improved transparency for our customers and patients,” said David M. Cordani, chairman and CEO of The Cigna
Group. “As we enter the new year, we are well‑positioned to build on this momentum, fueled by our innovations that leverage our diversified businesses and track record of strong financial performance.”
Shareholders’ net income for fourth quarter 2025 was $1.2 billion, or $4.64 per share. This compares with $1.4 billion, or $5.13 per share, for fourth quarter 2024.
The Cigna Group’s adjusted income from operations1 for fourth quarter
2025 was $2.1 billion, or $8.08 per share, compared with $1.8 billion, or $6.64 per share, for fourth quarter 2024.
Shareholders’ net income for 2025 was $6.0 billion, or $22.18 per
share. This compares with $3.4 billion, or $12.12 per share for 2024, which included a one-time non-cash after-tax investment loss of $2.7 billion, or $9.53 per share.
The Cigna Group’s adjusted income from operations1 for 2025 was $8.0 billion, or $29.84 per share, compared with $7.7 billion, or $27.33 per share, for 2024.
A reconciliation of shareholders’ net income to adjusted income from operations1 is provided on the following page and on Exhibit 1 of this earnings
release.
2
The following table includes highlights of results and reconciliations
of total revenues to adjusted revenues3 and shareholders’ net income to adjusted income from operations1:
Consolidated Financial Results (unaudited, dollars in millions):
|
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
||||||||||||||
|
|
2025
|
2024
|
2025
|
2024
|
||||||||||||
|
Total Revenues
|
$
|
72,472
|
$
|
65,649
|
$
|
274,900
|
$ |
247,121
|
||||||||
|
Net Investment Results from Equity Method Investments3
|
23
|
34
|
(249
|
)
|
(204
|
)
|
||||||||||
|
Special Item related to Impairment of dividend receivable3
|
—
|
—
|
—
|
182
|
||||||||||||
|
Adjusted Revenues3
|
$
|
72,495
|
$
|
65,683
|
$
|
274,651
|
$
|
247,099
|
||||||||
|
Consolidated Earnings, net of taxes
|
||||||||||||||||
|
Shareholders’ Net Income
|
$
|
1,234
|
$
|
1,424
|
$
|
5,957
|
$
|
3,434
|
||||||||
|
Net Investment (Gains) Losses1
|
104
|
(18
|
)
|
(90
|
)
|
2,529
|
||||||||||
|
Amortization of Acquired Intangible Assets1
|
327
|
375
|
1,325
|
1,347
|
||||||||||||
|
Special Items1
|
483
|
64
|
822
|
431
|
||||||||||||
|
Adjusted Income from Operations1
|
$
|
2,148
|
$
|
1,845
|
$
|
8,014
|
$
|
7,741
|
||||||||
|
|
||||||||||||||||
|
Shareholders’ Net Income, per share
|
$
|
4.64
|
$
|
5.13
|
$
|
22.18
|
$
|
12.12
|
||||||||
|
Adjusted Income from Operations1, per share
|
$
|
8.08
|
$
|
6.64
|
$
|
29.84
|
$
|
27.33
|
||||||||
| • |
Adjusted income from operations1 for fourth quarter 2025 increased 16% relative to fourth quarter 2024, driven by higher contributions primarily from Cigna Healthcare, as well as Evernorth Health Services.
|
| • |
Adjusted income from operations1 for 2025 increased 4% from 2024, reflecting strong growth in Evernorth Health Services, primarily within Specialty and Care Services.
|
| • |
The SG&A expense ratio4 and adjusted SG&A expense ratio4 were 5.0%
and 4.7% for fourth quarter 2025, compared to 5.9% and 5.7% in fourth quarter 2024, and 5.3% and 5.0% for full year 2025, compared to 6.0% and 5.9%,
for full year 2024, reflecting business mix shift.
|
| • |
The debt-to-capitalization ratio was 43.0% at December 31, 2025, compared to 44.9% at September 30, 2025 and 43.8% at December 31, 2024.
|
| • |
In 2025, the Company repurchased 11.9 million shares of common stock for approximately $3.6 billion.
|
| • |
On February 5, 2026, the Company’s Board of Directors declared a cash quarterly dividend of $1.56 per share of Cigna common stock to be paid on March 19, 2026 to shareholders of
record as of the close of trading on March 5, 2026. This reflects an increase from the 2025 cash quarterly dividend of $1.51 per share.
|
3
The following table summarizes The Cigna Group’s medical customers and overall customer relationships:
Customer Relationships (in thousands):
|
As of the Periods Ended
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Total Pharmacy Customers5
|
123,603
|
118,304
|
||||||
|
U.S. Healthcare
|
16,423
|
17,502
|
||||||
|
International Health
|
1,695
|
1,645
|
||||||
|
Total Medical Customers5
|
18,118
|
19,147
|
||||||
|
Behavioral Care
|
28,269
|
23,932
|
||||||
|
Dental
|
18,438
|
18,258
|
||||||
|
Medicare Part D
|
—
|
2,571
|
||||||
|
Total Customer Relationships5
|
188,428
|
182,212
|
||||||
| • |
Total customer relationships5 at December 31, 2025 increased 3% from December 31, 2024 to 188.4 million, reflecting new sales and the continued expansion of relationships in Pharmacy Benefit Services and Behavioral Care, partially offset by the HCSC transaction6.
|
| • |
Total pharmacy customers5 at December 31, 2025 increased 4% from December 31, 2024 to 123.6 million due to new sales and the continued expansion of relationships.
|
| • |
Total medical customers5 at December 31, 2025 decreased 5% from December 31, 2024 to 18.1 million, primarily reflecting the impact of the HCSC transaction6. Excluding the impact of the HCSC
transaction6, total medical customers5 as of December 31, 2025 were consistent with December 31, 2024.
|
| • |
Total behavioral customers5 at December 31, 2025 increased 18% from December 31, 2024 to 28.3 million due to the onboarding of a new government contract.
|
4
See Exhibit 1 for a reconciliation of adjusted income from operations1 to shareholders’ net income.
This segment includes the Pharmacy Benefit Services and Specialty and Care
Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.
Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network
administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty
distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.
Financial Results (dollars in millions):
|
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
||||||||||||||
|
|
2025
|
2024
|
2025
|
2024
|
||||||||||||
|
Total Adjusted Revenues
|
||||||||||||||||
|
Pharmacy Benefit Services
|
$
|
36,339
|
$
|
30,273
|
$
|
132,126
|
$
|
111,822
|
||||||||
|
Specialty and Care Services
|
$
|
26,717
|
$
|
23,471
|
$
|
102,827
|
$
|
90,333
|
||||||||
|
Adjusted Revenues3
|
$
|
63,056
|
$
|
53,744
|
$
|
234,953
|
$
|
202,155
|
||||||||
|
Adjusted Income from Operations, Pre-Tax
|
||||||||||||||||
|
Pharmacy Benefit Services
|
$
|
1,154
|
$
|
1,198
|
$
|
3,506
|
$
|
3,577
|
||||||||
|
Specialty and Care Services
|
$
|
1,034
|
$
|
948
|
$
|
3,715
|
$
|
3,424
|
||||||||
|
Adjusted Income from Operations, Pre-Tax1
|
$
|
2,188
|
$
|
2,146
|
$
|
7,221
|
$
|
7,001
|
||||||||
|
Margin, Pre-Tax7
|
3.5
|
%
|
4.0
|
%
|
3.1
|
%
|
3.5
|
%
|
||||||||
| • |
Evernorth Health Services fourth quarter 2025 adjusted revenues3 and adjusted income from operations, pre-tax1, increased 17% and 2%, respectively, relative to fourth quarter 2024. For full year 2025, adjusted revenues3 and adjusted income from
operations, pre-tax1, increased 16% and 3%,
respectively, relative to 2024.
|
| • |
For Pharmacy Benefit Services:
|
| ◦ |
Fourth quarter 2025
and full year 2025 adjusted revenues3 increased 20% and
18%, respectively, relative to the fourth quarter 2024 and full year 2024, reflecting strong organic growth, including the growth of existing client relationships, and new business.
|
| ◦ |
Fourth quarter 2025
and full year 2025 adjusted income from operations, pre-tax1, decreased 4% and 2%, relative to fourth quarter 2024 and full year 2024, reflecting strategic investments and
initiatives to support business growth and improve the patient experience.
|
| • |
For Specialty and Care Services:
|
| ◦ |
Fourth quarter 2025
and full year 2025 adjusted revenues3 both increased 14%,
relative to fourth quarter 2024 and full year 2024, reflecting strong specialty volume growth.
|
| ◦ |
Fourth quarter 2025
and full year 2025 adjusted income from operations, pre-tax1, increased 9% and 8%, respectively, relative to fourth
quarter 2024 and full year 2024, reflecting strong organic growth
in specialty businesses, including increased adoption of biosimilars.
|
5
This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and
customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual and family plan customers.
International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare included the Medicare and related businesses
until the divestiture of such businesses to Health Care Services Corporation (“HCSC”)6 on March 19, 2025.
Financial Results (dollars in millions):
|
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
||||||||||||||
|
|
2025
|
2024
|
2025
|
2024
|
||||||||||||
|
|
||||||||||||||||
|
Adjusted Revenues3,8
|
$
|
11,172
|
$
|
13,331
|
$
|
47,163
|
$
|
52,914
|
||||||||
|
Adjusted Income from Operations, Pre-Tax1
|
$
|
734
|
$
|
511
|
$
|
4,153
|
$
|
4,229
|
||||||||
|
Margin, Pre-Tax7
|
6.6
|
%
|
3.8
|
%
|
8.8
|
%
|
8.0
|
%
|
||||||||
| • |
Fourth quarter 2025
and full year 2025 adjusted revenues3,8 decreased 16%
and 11%, respectively, relative to fourth quarter 2024 and full year 2024, primarily reflecting the impact of the HCSC
transaction6,8. Excluding the impact of the HCSC transaction6,8, fourth quarter 2025 and full year 2025 adjusted revenues3,8 increased 8% and 7%, respectively, relative to fourth quarter 2024 and full year 2024, primarily driven by premium rate increases to cover expected increases in medical costs.
|
| • |
Fourth quarter 2025
adjusted income from operations, pre-tax1, increased 44% relative to fourth quarter 2024, primarily driven by higher
contributions from stop loss products relative to the prior year. Full year 2025 adjusted income from operations, pre-tax1, decreased
2% relative to full year 2024, primarily due to lower contributions
from the Individual and Family Plans business.
|
| • |
The Cigna Healthcare MCR4 was 88.0% for fourth quarter 2025, compared to 87.9% for fourth quarter 2024. The Cigna
Healthcare MCR4 was 84.4% for full year 2025, compared
to 83.2% for full year 2024, primarily due to higher medical
costs, driven by the Individual and Family Plans business.
|
| • |
Cigna Healthcare net medical costs payable9 was $4.09 billion at December 31, 2025, $4.53 billion at September 30, 2025, and $4.86 billion at December 31, 2024. The sequential decrease was consistent with prior years, reflecting stop loss seasonality. The
year-over-year decrease was primarily driven by the HCSC transaction6 which included $978 million in net medical costs payable9 at
December 31, 2024. Favorable prior year reserve development on a gross pre-tax basis was $342 million and $456 million for 2025
and 2024, respectively.
|
6
Corporate and Other Operations
Corporate reflects interest expense, amounts not allocated to operating segments
and includes intersegment eliminations. Other Operations is comprised of Corporate Owned Life Insurance (“COLI”), the Company’s run-off operations and other non-strategic businesses.
Financial Results (dollars in millions):
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
20243
|
|||||||||||||
|
Adjusted (Loss) from Operations, Pre-Tax1
|
$
|
(373
|
)
|
$
|
(424
|
)
|
$
|
(1,504
|
)
|
$
|
(1,697
|
)
|
||||
7
The Cigna Group’s outlook2 for full year 2026 adjusted revenues2,3
is approximately $280.0 billion. The Cigna Group’s outlook for full year 2026 consolidated adjusted income from operations1,2 is at least $7.950
billion, or at least $30.25 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2026
dividends.
|
(dollars in millions, except where noted and per share amounts)
|
|
|
2026 Consolidated Metrics
|
Projection for Full Year Ending
December 31, 2026
|
|
Adjusted Revenues2,3
|
~$280,000
|
|
Adjusted Income from Operations1,2
|
at least $7,950
|
|
Adjusted Income from Operations, per share1,2
|
at least $30.25
|
|
Adjusted SG&A Expense Ratio2,4
|
~5.0%
|
|
Adjusted Effective Tax Rate2,10
|
~19.0%
|
|
Cash Flow from Operations2
|
~$9,000
|
|
Capital Expenditures2
|
~$1,300
|
|
Shareholder Dividends2
|
~$1,600
|
|
Weighted Average Shares Outstanding (millions)2
|
261 to 265
|
|
2026 Evernorth Metrics
|
|
|
Evernorth Adjusted Income from Operations, Pre-Tax1,2
|
at least $6,900
|
|
2026 Cigna Healthcare Metrics
|
|
|
Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2
|
at least $4,500
|
|
Cigna Healthcare Medical Care Ratio2,4
|
83.7% to 84.7%
|
|
Total Medical Customers2,5
|
~18.1M
|
8
The foregoing statements represent the Company’s current estimates of The Cigna Group’s 2026 consolidated and segment adjusted income from operations1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number
of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.
This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations
section (https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review full year 2025 results and discuss full year 2026 outlook beginning today at
8:30 a.m. ET. A link to the conference call is available in the Investor Relations section of The Cigna Group’s website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx.
The call-in numbers for the conference call are as follows:
Live Call
(888) 566-1889 (Domestic)
(773) 799-3989 (International)
Passcode: 02052026
Replay
(866) 405-7290 (Domestic)
(203) 369-0603 (International)
It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better
future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health
Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has more than 185 million customer relationships around the world. Learn more at thecignagroup.com.
Notes:
| 1. |
Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents
the underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income
(or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna
Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of
the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income
(loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a reconciliation of consolidated adjusted
income from operations to shareholders’ net income.
|
9
| 2. |
Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income, on a forward-looking basis because it is
unable to predict, without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are
beyond The Cigna Group’s control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.
|
The Company’s outlook excludes the potential
effects of any other business combinations that may occur after the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2026 dividends.
The timing and actual number of shares repurchased will depend on a variety of factors, including price,
general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including
through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.
| 3. |
Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues
as total revenues excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special
items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or
future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a
reconciliation of consolidated adjusted revenues to total revenues.
|
| 4. |
Operating ratios are defined as follows:
|
| • |
The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through
guaranteed cost or experience-rated funding arrangements. Changes in percentages may be expressed in basis points (“bps”).
|
| • |
SG&A expense ratio on a GAAP basis for the fourth quarter 2025 represents enterprise selling, general and administrative expenses of $3,609
million as a percentage of total revenue of $72.5 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the fourth quarter 2024 represents enterprise selling, general and
administrative expenses of $3,865 million as a percentage of total revenue of $65.6 billion at a consolidated level.
|
| • |
SG&A expense ratio on a GAAP basis for the full year 2025 represents
enterprise selling, general and administrative expenses of $14,617 million as a percentage of total revenue of $274.9 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the full year 2024
represents enterprise selling, general and administrative expenses of $14,844 million as a percentage of total revenue of $247.1 billion at a consolidated level.
|
10
| • |
Adjusted SG&A expense ratio for the fourth quarter 2025 represents enterprise selling, general and administrative expenses of $3,430
million excluding special items of $179 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio
for the fourth quarter 2024 represents enterprise selling,
general and administrative expenses of $3,767 million excluding special items of $98 million as a percentage of adjusted revenue at a consolidated level.
|
| • |
Adjusted SG&A expense ratio for the full year 2025 represents enterprise selling, general and administrative expenses of $13,691 million
excluding special items of $926 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the full year 2024 represents enterprise selling, general and administrative expenses of $14,569
million excluding special items of $275 million as a percentage of adjusted revenue at a consolidated level.
|
| 5. |
Customer relationships are defined as follows:
|
| • |
Total medical customers includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy,
managed care arrangement, or administrative services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare’s provider network for covered services under their medical plan; or (iii) have medical claims that are
administered by Cigna Healthcare.
|
| • |
Total customer relationships and total medical customers as of December 31, 2024, excluding the impact of the HCSC transaction6, were
179,712 thousand and 18,055 thousand, respectively.
|
| 6. |
On March 19, 2025, the company completed the sale (the “HCSC transaction”) of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans,
Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Services Corporation (“HCSC”).
|
| 7. |
Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.
|
| 8. |
The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include
the Company’s share of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.
|
Set forth below is a table that presents the impact of the HCSC transaction on Cigna Healthcare Adjusted
Revenues for the periods presented. Management believes that the presentation of this measure is useful to investors because it permits a comparison of the Company’s go-forward business across periods.
Financial Results (dollars in millions):
|
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
||||||||||||||
|
|
2025
|
2024
|
2025
|
2024
|
||||||||||||
|
|
||||||||||||||||
|
Cigna Healthcare Adjusted Revenues3
|
$
|
11,172
|
$
|
13,331
|
$
|
47,163
|
$
|
52,914
|
||||||||
|
Less: U.S. Healthcare - divested businesses revenues
|
—
|
2,973
|
3,850
|
12,348
|
||||||||||||
|
Cigna Healthcare Adjusted Revenues3 excluding U.S. Healthcare - divested businesses revenues
|
$
|
11,172
|
$
|
10,358
|
$
|
43,313
|
$
|
40,566
|
||||||||
11
| 9. |
Medical costs payable within the Cigna Healthcare segment are presented
net of reinsurance and other recoverables. The gross medical costs payable balance was $4.24 billion as of December 31, 2025, $4.68 billion as of September 30, 2025, and $5.02 billion as of December
31, 2024.
|
| 10. |
The measure “adjusted effective tax rate” is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable
GAAP measure, “consolidated effective tax rate”. We define adjusted effective tax rate as the consolidated income tax rate applicable to the Company’s pre-tax income excluding pre-tax income (loss) attributable to noncontrolling interests,
net investment results, amortization of acquired intangible assets, and special items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of
accounting are also excluded. Management is not able to provide a reconciliation to the consolidated effective tax rate on a forward-looking basis because we are unable to predict, without unreasonable effort, certain components thereof
including (i) future net investment results and (ii) future special items.
|
12
This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may
include, among others, statements concerning our projected outlook for 2026 (including
adjusted revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective tax rate; cash flow from operations; capital expenditures; shareholder dividends; weighted average
shares outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or
operational initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; capital deployment
plans and amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or
performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of
similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or
implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage healthcare costs and respond to price competition, inflation and other pressures that could compress our margins or result in
premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly
changing industry; changes in drug pricing or industry pricing benchmarks; our ability to efficiently transition to a new rebate-free pricing model; our ability
to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our
estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in
connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in
government-sponsored programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data
laws, regulations and standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our
information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence
on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational
operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations
which could lead to an impairment charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics,
stock market or changes in interest rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk
related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You
should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict
or quantify. The Cigna Group undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.
13
|
THE CIGNA GROUP
|
Exhibit 1
|
|||||||||||||||
|
COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)
|
||||||||||||||||
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
|||||||||||||||
|
(Dollars in millions, except per share amounts)
|
2025
|
2024
|
2025
|
2024
|
||||||||||||
|
REVENUES
|
||||||||||||||||
|
Pharmacy revenues
|
$
|
58,336
|
$
|
49,941
|
$
|
216,672
|
$
|
185,362
|
||||||||
|
Premiums
|
9,288
|
11,503
|
40,261
|
45,996
|
||||||||||||
|
Fees and other revenues
|
4,509
|
3,928
|
16,921
|
14,790
|
||||||||||||
|
Net investment income
|
339
|
277
|
1,046
|
973
|
||||||||||||
|
Total revenues
|
72,472
|
65,649
|
274,900
|
247,121
|
||||||||||||
|
Net investment results from certain equity method investments
|
23
|
34
|
(249
|
) |
(204
|
)
|
||||||||||
|
Special item related to impairment of dividend receivable
|
—
|
—
|
—
|
182
|
||||||||||||
|
Adjusted revenues (1)
|
$
|
72,495
|
$
|
65,683
|
$
|
274,651
|
$
|
247,099
|
||||||||
|
Shareholders’ net income
|
$
|
1,234
|
$
|
1,424
|
$
|
5,957
|
$
|
3,434
|
||||||||
|
Pre-tax adjusted income (loss) from operations by segment
|
||||||||||||||||
|
Evernorth Health Services
|
$
|
2,188
|
$
|
2,146
|
$
|
7,221
|
$
|
7,001
|
||||||||
|
Cigna Healthcare
|
734
|
|
511
|
4,153
|
4,229
|
|||||||||||
|
Corporate and Other Operations
|
(373
|
) |
(424
|
) |
(1,504
|
) |
(1,697
|
)
|
||||||||
|
Adjusted income tax expense
|
(401
|
) |
(388
|
) |
(1,856
|
) |
(1,792
|
)
|
||||||||
|
Consolidated after-tax adjusted income from
operations
|
$
|
2,148
|
$
|
1,845
|
$
|
8,014
|
$
|
7,741
|
||||||||
|
Weighted average shares (in thousands)
|
265,699
|
277,784
|
268,563
|
283,218
|
||||||||||||
|
Common shares outstanding (in thousands)
|
263,464
|
273,789
|
||||||||||||||
|
SHAREHOLDERS’ EQUITY at December
31,
|
$
|
41,713
|
$
|
41,033
|
||||||||||||
|
SHAREHOLDERS’ EQUITY PER SHARE at December
31,
|
$
|
158.33
|
$
|
149.87
|
||||||||||||
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
|||||||||||||||||||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||||||||||||||||||
|
(Dollars in millions, except per share amounts)
|
Pre-tax
|
After-tax
|
Pre-tax
|
After-tax
|
Pre-tax
|
After-tax
|
Pre-tax
|
After-tax
|
||||||||||||||||||||||||
|
SHAREHOLDERS’ NET INCOME
|
||||||||||||||||||||||||||||||||
|
Shareholders’ net income
|
$
|
1,234
|
$
|
1,424
|
$
|
5,957
|
$
|
3,434
|
||||||||||||||||||||||||
|
Adjustments to reconcile adjusted income from operations
|
||||||||||||||||||||||||||||||||
|
Net investment losses (gains) (2)
|
$
|
123
|
104
|
$
|
(34
|
)
|
(18
|
)
|
$
|
(225
|
)
|
(90
|
)
|
$
|
2,533
|
2,529
|
||||||||||||||||
|
Amortization of acquired intangible assets
|
463
|
327
|
424
|
375
|
1,743
|
1,325
|
1,703
|
1,347
|
||||||||||||||||||||||||
|
Special Items
|
||||||||||||||||||||||||||||||||
|
Deferred tax expenses, net
|
—
|
374
|
—
|
9
|
—
|
427
|
—
|
84
|
||||||||||||||||||||||||
|
Strategic optimization program
|
183
|
136
|
—
|
—
|
749
|
565
|
—
|
—
|
||||||||||||||||||||||||
|
Integration and transaction-related costs
|
30
|
21
|
98
|
76
|
327
|
247
|
275
|
211
|
||||||||||||||||||||||||
|
Net loss (gain) on sale of businesses
|
66
|
(48
|
)
|
(130
|
)
|
(21
|
)
|
(13
|
)
|
(404
|
)
|
(24
|
)
|
(2
|
)
|
|||||||||||||||||
|
Benefits associated with litigation matters
|
—
|
—
|
—
|
—
|
(17
|
)
|
(13
|
)
|
—
|
—
|
||||||||||||||||||||||
|
Impairment of dividend receivable
|
—
|
—
|
—
|
—
|
—
|
—
|
182
|
138
|
||||||||||||||||||||||||
|
Adjusted income from operations (3)
|
$
|
2,148
|
$
|
1,845
|
$
|
8,014
|
$
|
7,741
|
||||||||||||||||||||||||
|
DILUTED EARNINGS PER SHARE
|
||||||||||||||||||||||||||||||||
|
Shareholders’ net income
|
$
|
4.64
|
$
|
5.13
|
$
|
22.18
|
$
|
12.12
|
||||||||||||||||||||||||
|
Adjustments to reconcile to adjusted income from operations
|
||||||||||||||||||||||||||||||||
|
Net investment losses (gains) (2)
|
$
|
0.46
|
0.39
|
$
|
(0.12
|
)
|
(0.06
|
)
|
$
|
(0.84
|
)
|
(0.34
|
)
|
$
|
8.95
|
8.93
|
||||||||||||||||
|
Amortization of acquired intangible assets
|
1.74
|
1.23
|
1.53
|
1.34
|
6.50
|
4.94
|
6.01
|
4.76
|
||||||||||||||||||||||||
|
Special Items
|
||||||||||||||||||||||||||||||||
|
Deferred tax expenses, net
|
—
|
1.41
|
—
|
0.03
|
—
|
1.59
|
—
|
0.30
|
||||||||||||||||||||||||
|
Strategic optimization program
|
0.69
|
0.51
|
—
|
—
|
2.78
|
2.10
|
—
|
—
|
||||||||||||||||||||||||
|
Integration and transaction-related costs
|
0.11
|
0.08
|
0.35
|
0.27
|
1.22
|
0.92
|
0.97
|
0.75
|
||||||||||||||||||||||||
|
Net loss (gain) on sale of businesses
|
0.25
|
(0.18
|
)
|
(0.47
|
)
|
(0.07
|
)
|
(0.05
|
)
|
(1.50
|
)
|
(0.08
|
)
|
(0.02
|
)
|
|||||||||||||||||
|
Benefits associated with litigation matters
|
—
|
—
|
—
|
—
|
(0.06
|
)
|
(0.05
|
)
|
—
|
—
|
||||||||||||||||||||||
|
Impairment of dividend receivable
|
—
|
—
|
—
|
—
|
—
|
—
|
0.64
|
0.49
|
||||||||||||||||||||||||
|
Adjusted income from operations (3)
|
$
|
8.08
|
$
|
6.64
|
$
|
29.84
|
$
|
27.33
|
||||||||||||||||||||||||
(1) Adjusted revenues is defined as total revenues excluding the following
adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of
past or future underlying performance of our businesses.
(2) Includes Net investment gains/losses as presented in our Consolidated
Statements of Income, as well as the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our
Consolidated Statements of Income.
(3) Adjusted income (loss) from operations is defined as shareholders’ net income
(or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of acquired intangible assets and special
items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.